<unk> (Duzallo) is a combination of<unk> , a URAT1 inhibitor, and Allopurinol, a xanthine oxidase inhibitor that is FDA approved for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of Allopurinol alone. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include headache, influenza, blood creatinine increased, gastroesophageal reflux disease, and skin rash.
Lesinurad / allopurinol 
Sulfacetamide sodium And Prednisolone acetate
Acetaminophen, aspirin and salicylamide
Niacin/simvastatin
Niacin/lovastatin
Niacin/Simvastatin
Allopurinol 
Enalapril\Hydrochlorothiazide